New and recently funded Medical Startups
1
Country: USA | Funding: $298.3M
Cala Health is a medical technology company pioneering a new class of electrical medicine called neuroperipheral therapy. Neuroperipheral therapy has the potential to address chronic disease by externally stimulating peripheral nerves with body-worn electronics. Cala Health is bringing together experts in neuroscience, consumer electronics, and medical devices to develop accessible therapies that treat chronic disease non-invasively.
Cala Health is a medical technology company pioneering a new class of electrical medicine called neuroperipheral therapy. Neuroperipheral therapy has the potential to address chronic disease by externally stimulating peripheral nerves with body-worn electronics. Cala Health is bringing together experts in neuroscience, consumer electronics, and medical devices to develop accessible therapies that treat chronic disease non-invasively.
2
Country: USA | Funding: $163M
AcuityMD is a targeting platform for medical device companies that automatically uncovers new opportunities and keeps track of existing users across each of the products you sell. Stop the manual research and data entry and start connecting with your future users.
AcuityMD is a targeting platform for medical device companies that automatically uncovers new opportunities and keeps track of existing users across each of the products you sell. Stop the manual research and data entry and start connecting with your future users.
3
Country: UK | Funding: $205.5M
Pulmocide develops inhaled medications for the treatment of viral and fungal respiratory tract infections. The company's lead drug, opelconazole, is in Phase 3 clinical trials for the treatment of patients with invasive pulmonary aspergillosis. Aspergillus is a genus of fungi whose spores are airborne and can cause severe, often life-threatening, lung disease in people with weakened immune systems or pre-existing lung conditions. Opelconazole has received several FDA approvals that may expedite its development and/or review, including orphan drug designation, fast-track designation, and qualified infectious disease product (QIDP) designation. It has also received orphan drug designation in the European Union.
Pulmocide develops inhaled medications for the treatment of viral and fungal respiratory tract infections. The company's lead drug, opelconazole, is in Phase 3 clinical trials for the treatment of patients with invasive pulmonary aspergillosis. Aspergillus is a genus of fungi whose spores are airborne and can cause severe, often life-threatening, lung disease in people with weakened immune systems or pre-existing lung conditions. Opelconazole has received several FDA approvals that may expedite its development and/or review, including orphan drug designation, fast-track designation, and qualified infectious disease product (QIDP) designation. It has also received orphan drug designation in the European Union.
4
Country: China | Funding: $215.2M
Connect Biopharmaceuticals is a developer of novel immune modulators for the treatment of serious autoimmune diseases and inflammation like asthma and COPD. The Company’s lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha and has demonstrated activity in both atopic dermatitis and asthma. It has a distinct epitope that is different from dupilumab and has achieved equivalent effects with lower concentration than dupilumab. The company is also building a deep and compelling pipeline of product candidates with the potential to advance care and outcomes for patients with diverse autoimmune or inflammatory diseases.
Connect Biopharmaceuticals is a developer of novel immune modulators for the treatment of serious autoimmune diseases and inflammation like asthma and COPD. The Company’s lead product candidate, rademikibart, is an antibody designed to target interleukin-4 receptor alpha and has demonstrated activity in both atopic dermatitis and asthma. It has a distinct epitope that is different from dupilumab and has achieved equivalent effects with lower concentration than dupilumab. The company is also building a deep and compelling pipeline of product candidates with the potential to advance care and outcomes for patients with diverse autoimmune or inflammatory diseases.
5
Country: USA | Funding: $4.3B
Revolution Medicines develops novel treatments for cancers associated with RAS activation (which accounts for 30 percent of all new human cancer diagnoses). The company is building a portfolio of RAS(ON) inhibitors using its tricomplex inhibitor platform, which provides unprecedented access to the active form of oncogenic RAS. Revolution Medicines is building a comprehensive pipeline of targeted therapies for the discovery, development, and delivery of new therapeutic options for PDAC, NSCLC, and solid tumors. The pipeline is designed to allow the evaluation of compounds as monotherapies and in combination with existing standard-of-care therapies and/or other compounds within our portfolio.
Revolution Medicines develops novel treatments for cancers associated with RAS activation (which accounts for 30 percent of all new human cancer diagnoses). The company is building a portfolio of RAS(ON) inhibitors using its tricomplex inhibitor platform, which provides unprecedented access to the active form of oncogenic RAS. Revolution Medicines is building a comprehensive pipeline of targeted therapies for the discovery, development, and delivery of new therapeutic options for PDAC, NSCLC, and solid tumors. The pipeline is designed to allow the evaluation of compounds as monotherapies and in combination with existing standard-of-care therapies and/or other compounds within our portfolio.
6
Country: USA | Funding: $1.1B
Click Therapeutics is looking to boost work on an online platform of “prescription digital therapeutics.” The company’s leading product is Clickotine, deisgned for smoking cessation, that works as a phone app designed to help people stop smoking using input from Magellan Health, a behavioral healthcare company.
Click Therapeutics is looking to boost work on an online platform of “prescription digital therapeutics.” The company’s leading product is Clickotine, deisgned for smoking cessation, that works as a phone app designed to help people stop smoking using input from Magellan Health, a behavioral healthcare company.
7
Country: France | Funding: $219.7M
Enterome develops breakthrough immunomodulatory drugs for cancer treatment – OncoMimics peptides – based on the interaction between the gut microbiome and the immune system. The company's candidates target a wide range of tumor types (glioblastoma, adrenal tumors, non-Hodgkin's lymphoma, and colorectal cancer). OncoMimics are a specific combination of bacterial peptides derived from bacteria present in the gut microbiome that precisely mimic either overexpressed tumor-associated antigens or specific markers in solid and liquid tumors, respectively. The company has developed a drug discovery platform that enables the analysis of the world's largest microbiome protein database and the creation of new drugs.
Enterome develops breakthrough immunomodulatory drugs for cancer treatment – OncoMimics peptides – based on the interaction between the gut microbiome and the immune system. The company's candidates target a wide range of tumor types (glioblastoma, adrenal tumors, non-Hodgkin's lymphoma, and colorectal cancer). OncoMimics are a specific combination of bacterial peptides derived from bacteria present in the gut microbiome that precisely mimic either overexpressed tumor-associated antigens or specific markers in solid and liquid tumors, respectively. The company has developed a drug discovery platform that enables the analysis of the world's largest microbiome protein database and the creation of new drugs.
8
Country: USA | Funding: $22M
Keebler Health is a developer of an AI-based risk adjustment tool for healthcare providers.
Keebler Health is a developer of an AI-based risk adjustment tool for healthcare providers.
9
Country: USA | Funding: $125.4M
Calyxo has developed the CVAC surgical system for kidney stone removal and the corresponding procedure called SURE. The company's device utilizes irrigation and vacuum aspiration during and after laser lithotripsy to extract stones from patients' kidneys, allowing physicians to completely remove stone fragments. Independent irrigation and aspiration channels ensure continuous flow. Four angled nozzles liquefy fragments for effective removal. Dynamic aspiration removes dust during lithotripsy and removes fragments after lithotripsy. The CVAC system demonstrated safety and superior stone removal in the landmark ASPIRE study.
Calyxo has developed the CVAC surgical system for kidney stone removal and the corresponding procedure called SURE. The company's device utilizes irrigation and vacuum aspiration during and after laser lithotripsy to extract stones from patients' kidneys, allowing physicians to completely remove stone fragments. Independent irrigation and aspiration channels ensure continuous flow. Four angled nozzles liquefy fragments for effective removal. Dynamic aspiration removes dust during lithotripsy and removes fragments after lithotripsy. The CVAC system demonstrated safety and superior stone removal in the landmark ASPIRE study.
10
Country: Israel | Funding: $274M
Nanox Medical develops and manufactures radiographic devices enabling lower radiation dose, higher image resolution and high degree of automation. The company has developed secondary fluorescence technology, which offers significant advantages over traditional Coolidge tubes. Its flagship device - miniC - is a multifunctional, battery-operated, miniature C-arm X-ray system. It provides images and video for orthopedic surgeries, pediatric surgeries and clinical diagnostics. Nanox also produces miniDR-85 - a portable X-ray unit powered by a 60V lithium battery. It is used for diagnostic imaging in medical facilities and emergency situations.
Nanox Medical develops and manufactures radiographic devices enabling lower radiation dose, higher image resolution and high degree of automation. The company has developed secondary fluorescence technology, which offers significant advantages over traditional Coolidge tubes. Its flagship device - miniC - is a multifunctional, battery-operated, miniature C-arm X-ray system. It provides images and video for orthopedic surgeries, pediatric surgeries and clinical diagnostics. Nanox also produces miniDR-85 - a portable X-ray unit powered by a 60V lithium battery. It is used for diagnostic imaging in medical facilities and emergency situations.
